MARKET

MNTA

MNTA

Momenta Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

15.71
-2.36
-13.06%
After Hours: 15.94 +0.23 +1.46% 18:58 12/11 EST
OPEN
17.74
PREV CLOSE
18.07
HIGH
17.74
LOW
15.31
VOLUME
1.65M
TURNOVER
--
52 WEEK HIGH
18.39
52 WEEK LOW
9.51
MARKET CAP
1.55B
P/E (TTM)
-7.2590
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MNTA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

MNTA News

  • Here�s Why Momenta Pharmaceuticals Stock Dropped Today
  • MotleyFool.com.10h ago
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.18h ago
  • The Daily Biotech Pulse: Correvio Faces FDA Panel Rejection, Iterum's Antibiotic Trial Narrowly Misses Primary Endpoint
  • Benzinga.18h ago
  • Momenta to pay $35M to settle Tennessee antitrust case
  • seekingalpha.1d ago

More

Industry

Biotechnology & Medical Research
-0.34%
Pharmaceuticals & Medical Research
+0.06%

Hot Stocks

Name
Price
%Change

About MNTA

Momenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.
More

Webull offers Momenta Pharmaceuticals, Inc. (MNTA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.